Stribild, a Single Tablet Regimen for the Treatment of HIV Disease

ConclusionStribild had a favorable safety profile in the two recently published randomized, double-blind, phase 3 clinical trials. With the approval of Stribild, clinicians now have more flexibility in prescribing single-tablet regimens for patients.

https://link.springer.com/10.1007/s13556-013-0001-y

Source: Combination Products in Therapy - December 1, 2013 Category: Drugs & Pharmacology Source Type: research